Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma

Radiother Oncol. 2009 Jul;92(1):89-95. doi: 10.1016/j.radonc.2009.01.010. Epub 2009 Mar 28.

Abstract

Background and purpose: To confirm the feasibility of accelerator-based BNCT (AB-BNCT) for treatment of multiple liver tumors and malignant pleural mesothelioma (MPM), we compared dose distribution and irradiation time between AB-BNCT and reactor-based BNCT (RB-BNCT).

Material and methods: We constructed treatment plans for AB-BNCT and RB-BNCT of four multiple liver tumors and six MPM. The neutron beam data on RB-BNCT were those from the research reactor at Kyoto University Research Reactor Institute (KURRI). The irradiation time and dose-volume histogram data were assessed for each BNCT system.

Results: In BNCT for multiple liver tumors, when the 5 Gy-Eq dose was delivered as the mean dose to the healthy liver tissues, the mean dose delivered to the liver tumors by AB-BNCT and RB-BNCT was 68.1 and 65.1 Gy-Eq, respectively. In BNCT for MPM, when the mean lung dose to the normal ipsilateral lung was 5 Gy-Eq, the mean dose delivered to the MPM tumor by AB-BNCT and RB-BNCT was 20.2 and 19.9 Gy-Eq, respectively. Dose distribution analysis revealed that AB-BNCT is superior to RB-BNCT for treatment of deep-seated tumors.

Conclusions: The feasibility of the AB-BNCT system constructed at our institute was confirmed from a clinical viewpoint in BNCT for multiple liver tumors and MPM.

Publication types

  • Comparative Study

MeSH terms

  • Boron Compounds / therapeutic use*
  • Boron Neutron Capture Therapy / methods*
  • Dose-Response Relationship, Radiation
  • Feasibility Studies
  • Female
  • Humans
  • Liver Neoplasms / radiotherapy*
  • Male
  • Mesothelioma / radiotherapy*
  • Pleural Neoplasms / radiotherapy*
  • Radiotherapy Dosage
  • Treatment Outcome

Substances

  • Boron Compounds